MC
PCVX icon

Maverick Capital’s Vaxcyte PCVX Stock Holding History

Maverick Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.1M Buy
1,377,738
+23,501
+2% +$1.28M 0.92% 35
2025
Q4 		$62.5M Buy
1,354,237
+64,670
+5% +$2.89M 0.67% 38
2025
Q3 		$46.5M Sell
1,289,567
-21,038
-2% -$697K 0.62% 43
2025
Q2 		$42.6M Buy
1,310,605
+102,512
+8% +$3.36M 0.64% 43
2025
Q1 		$45.6M Buy
1,208,093
+6,195
+0.5% +$495K 0.81% 43
2024
Q4 		$98.4M Buy
1,201,898
+225,649
+23% +$22.4M 1.77% 23
2024
Q3 		$112M Buy
976,249
+288,341
+42% +$26M 2.18% 17
2024
Q2 		$51.9M Buy
687,908
+332,777
+94% +$22.7M 0.99% 32
2024
Q1 		$24.3M Buy
+355,131
New +$24.6M 0.46% 52

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital's PCVX Position: Q1 2026 in Review

Maverick Capital increased its Vaxcyte (PCVX) stake by 1.7% in Q1 2026, buying an estimated $1.28M and bringing the position to 1,377,738 shares worth $80.1M. The position accounts for 0.92% of the portfolio, ranked #35.

Maverick Capital first reported a position in PCVX in Q1 2024 and has held it in 9 quarters since. The position peaked at $112M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Maverick Capital held 1,377,738 shares of Vaxcyte worth $80.1M as of Q1 2026.
  • Maverick Capital bought 23,501 Vaxcyte shares in Q1 2026, an estimated $1.28M.
  • Vaxcyte made up 0.92% of Maverick Capital's portfolio in Q1 2026, its #35 holding.
  • Maverick Capital first reported a position in Vaxcyte in Q1 2024 and has held it in 9 quarters since.
  • Maverick Capital's Vaxcyte position peaked at $112M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Maverick Capital's 13F filing for Q1 2026, filed 15 May 2026.